Design Therapeutics Inc

NASDAQ DSGN

Data sourced from iex and EODHD
Download Data

Design Therapeutics Inc Income Statement 2020 - 2024

This table shows the Income Statement for Design Therapeutics Inc going from 2020 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31
Revenue
M 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cost of Revenue
M 0 0 0 0 0 0 - - - - - - - - - - -
Gross Profit
M 0 1 0 0 0 0 - - - - - - - - 0 0 0
Operating Expenses
M 14 16 19 22 22 19 - - - - - - - - 2 1 1
Selling, General, and Administrative Expenses (SG&A)
M 5 4 6 6 6 5 5 4 5 4 3 3 2 1 0 0 0
Research and Development (R&D) Expenses
M 10 11 13 17 16 14 14 11 9 7 9 5 4 3 2 1 0
Other Operating Expenses
M 0 1 0 0 0 0 - - - - - - - - 0 0 0
Costs and Expenses
M 14 15 19 22 22 19 - - - - - - - - - - -
Operating Income
M -14 -15 -19 -23 -22 -19 -19 -16 -13 -11 -11 -8 -6 -4 -2 -1 -1
Interest Expense
M - 0 - - 0 2 1 1 0 0 - - - - - - -
Non-operating Income/Expense
M 3 3 3 3 2 2 1 1 0 0 0 0 0 0 0 0 0
EBT
M -11 -12 -16 -20 -19 -17 -18 -15 -13 -11 -11 -8 -6 -4 -2 -1 -1
Income Tax Provision
M - 2 0 - -2 -2 -1 -1 0 0 - - - - - - -
Income after Tax
M - -14 -16 - -17 -15 -16 -14 -13 -11 - - - - - - -
Non-Controlling Interest
M - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Net Income
M - - - -20 -19 -17 -18 -15 -13 -11 -11 -8 -6 - -2 -1 -1
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 56,488,527.00 56,151,619.00 55,988,691.00 55,948,990.00 55,908,033.00 55,864,872.00 55,782,329.00 55,670,780.00 55,507,338.00 55,362,390.00 55,155,030.00 55,081,397.00 17,630,178.00 27,193,045.00 27,193,045.00 27,193,045.00 27,193,045.00
EBITDA
M -14 -15 -19 -22 -22 -19 -19 -16 -13 -11 -11 -8 -6 -4 -2 -1 -1
Depreciation and Amortization
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - -
EBIT
M -14 -15 -19 -23 -22 -20 -19 -16 -13 -11 -11 -8 -6 -4 -2 -1 -1
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% - -21.06 0.87 - 12.22 12.55 8.40 4.27 0.79 0.56 - - - - - - -
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Gross Profit Margin
% - 83.53 - - - - - - - - - - - - 100.00 100.00 100.00
Operating Income Margin
% - -1,804.42 - - - - - - - - - - - - -11,915.00 -4,719.35 -438.73
Net Income Margin
% - - - - - - - - - - - - - - -11,600.00 -4,651.61 -466.90
EBITDA Ratio
% - -1,787.95 - - - - - - - - - - - - -11,910.00 -4,719.35 -438.73
EBIT Ratio
% - -1,804.42 - - - - - - - - - - - - -11,915.00 -4,719.35 -438.73
EBT Ratio
% - -1,413.13 - - - - - - - - - - - - -11,600.00 -4,651.61 -466.90

StockViz Staff

September 16, 2024

Any question? Send us an email